← Back to Search

regadenoson infusion with contrast-enhanced ultrasound for Sickle Cell Disease

N/A
Waitlist Available
Led By Jonathon Lindner, MD
Research Sponsored by Versiti
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 years
Awards & highlights

Study Summary

This study is evaluating whether contrast-enhanced ultrasound can be used to detect changes in blood flow in people with sickle cell disease.

Eligible Conditions
  • Sickle Cell Disease
  • Sickle Cell Anemia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Microvascular Blood Flow in Sickle Cell Anemia with Regadenoson Use
Secondary outcome measures
Changes in Microvascular Blood Flow in Subjects with Sickle Cell Anemia During a Pain Crisis
Microvascular Blood Flow in Sickle Cell Anemia Subjects Versus Control Subjects

Trial Design

5Treatment groups
Experimental Treatment
Group I: Technique Optimization ControlsExperimental Treatment1 Intervention
Healthy volunteers will undergo contrast-enhanced ultrasound.
Group II: Sickle Cell Controls ARMExperimental Treatment1 Intervention
Adult subjects with sickle cell anemia will receive contrast-enhanced ultrasound
Group III: Sickle Cell CEU ARMExperimental Treatment1 Intervention
Adults subjects with sickle cell anemia will receive contrast-enhanced ultrasound
Group IV: Regadenoson ARMExperimental Treatment1 Intervention
Adult subjects with sickle cell anemia will receive a regadenoson infusion with contrast-enhanced ultrasound
Group V: Healthy Control ARMExperimental Treatment1 Intervention
Healthy African American control subjects without sickle cell anemia will receive contrast-enhanced ultrasound

Find a Location

Who is running the clinical trial?

University of Illinois at ChicagoOTHER
609 Previous Clinical Trials
1,559,109 Total Patients Enrolled
La Jolla Institute for Allergy & ImmunologyOTHER
4 Previous Clinical Trials
3,176 Total Patients Enrolled
Oregon Health and Science UniversityOTHER
975 Previous Clinical Trials
7,386,012 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
New England Journal of MedicineJournal
Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia
Charache, Samuel, Michael L. Terrin, Richard D. Moore, George J. Dover, Franca B. Barton, Susan V. Eckert, Robert P. McMahon, and Duane R. Bonds. 1995. “Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia”. New England Journal of Medicine. Massachusetts Medical Society. doi:10.1056/nejm199505183322001.
clinicaltrials.govStudy
Microvascular Blood Flow in Sickle Cell Anemia
Joshua Field 2012. "Microvascular Blood Flow in Sickle Cell Anemia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01566890.
All > Autoimmune Hemolytic Anemia > Sickle Cell Anemia
~16 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top